The MHRA’s 2025-2026 equality duty report outlines three actionable mechanisms through which pharmaceutical regulators can advance health equity. First, systematic equality impact assessments are now integral to medicine approval and safety monitoring, requiring explicit evaluation of how regulatory decisions affect protected characteristic groups—a procedural safeguard previously absent from standard practice.
Second, the agency has restructured public engagement to actively solicit input from underrepresented communities, recognizing that regulatory decisions affecting health outcomes require diverse stakeholder participation. Third, internal workforce diversity metrics demonstrate measurable improvements in regulatory team composition, particularly in senior positions.
For healthcare professionals and policy stakeholders, these reforms indicate that health equity advancement requires concrete institutional mechanisms rather than aspirational commitments. The MHRA model demonstrates how regulatory agencies can systematically evaluate differential health impacts, broaden democratic participation in regulatory processes, and foster inclusive institutional culture—practical steps applicable across healthcare governance structures.
Read the full article on GMJ Newsroom.
Was this article helpful?
